Hsbc Holdings PLC Taysha Gene Therapies, Inc. Transaction History

Hsbc Holdings PLC

$168 Billion
Q3 2024

A detailed history of Hsbc Holdings PLC transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 12,315 shares of TSHA stock, worth $21,674. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,315

Holding current value

$21,674

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2024 Nov 14, 2024	BUY	$2.01 - $2.46 $24,753 - $30,294	12,315 New	12,315 $24,000
Q2 2022 Aug 11, 2022	BUY	$2.47 - $6.77 $40,927 - $112,178	16,570 New	16,570 $63,000

Others Institutions Holding TSHA

# of Institutions

117

Shares Held

136M

Call Options Held

25.9K

Put Options Held

24K

Avoro Capital Advisors LLC New York, NY

18.7M
Shares

$32.8 Million
0.56% of portfolio
Rtw Investments, LP New York, NY

14.9M
Shares

$26.3 Million
0.48% of portfolio
Black Rock Inc. New York, NY

11.7M
Shares

$20.7 Million
0.0% of portfolio
Ra Capital Management, L.P. Boston, MA

10.9M
Shares

$19.1 Million
0.3% of portfolio
Vr Adviser, LLC New York, NY

9M
Shares

$15.8 Million
1.87% of portfolio

View Full List

About Taysha Gene Therapies, Inc.

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $85.1M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

More about TSHA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Account